Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Top Cited Papers
- 1 November 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 378 (9805), 1779-1787
- https://doi.org/10.1016/s0140-6736(11)61649-8
Abstract
No abstract availableKeywords
Funding Information
- Biogen Idec
- F. Hoffmann-La Roche
This publication has 27 references indexed in Scilit:
- Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringThe Lancet Neurology, 2011
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging studyArthritis & Rheumatism, 2008
- Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damageBrain, 2007
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- Myelin oligodendrocyte glycoprotein–specific T and B cells cooperate to induce a Devic-like disease in miceJCI Insight, 2006
- Rating neurologic impairment in multiple sclerosisNeurology, 1983